General Information of the Drug (ID: M6APDG00567)
Name
Erythromycin stearate
Synonyms
Eratrex; Erypar; Erythrocin stearate; Erythromycin octadecanoate (salt); Erythromycin stearate (salt); Erythromycin stearate [BAN:JAN]; Erythromycin steraric acid salt; Erythromycin, stearate (salt); Ethril; Ethril 250; Gallimycin; HSDB 4178; LXW024X05M; Meberyt; NCI-C55674; OE 7; Octadecanoic acid, compd. with erythromycin (1:1); Pfizer-E; Qidmycin; Stearic acid, compd. with erythromycin (1:1); UNII-LXW024X05M; Wyamycin S; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erygel; Erymax; Erythra-Derm; Erythro-Statin; Erythrocin; Erythromycin; Erythrogran; Erythroguent; Erythromid; Erythromycin A; Erythromycin base; Erythromycine; Erythromycinum; Ilocaps; Ilotycin; Mephamycin; Pantomicina; Propiocine; R-P Mycin; Robimycin; Sansac; Stiemycin; Torlamicina; Wemid; Erythro; (-)-ERYTHROMYCIN; 114-07-8; Abboticin; Abomacetin; Akne-Mycin; Benzamycin; Dotycin; Dumotrycin; E-Base; E-Glades; E-Mycin; E-Solve 2; Emgel; Eritrocina; Eritromicina; Ery-Tab; Eryacne; Eryc 125; Eryc Sprinkles; 643-22-1; Abboticine; Bristamycin; CCRIS 1504; Dowmycin E; EINECS 211-396-1; ERYTHROMYCIN STEARATE; ETHRIL 500
    Click to Show/Hide
Status
Approved
Structure
3D MOL
Formula
C55H103NO15
InChI
1S/C37H67NO13.C18H36O2/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-17H2,1H3,(H,19,20)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;/m1./s1
InChIKey
YAVZHCFFUATPRK-YZPBMOCRSA-N
PubChem CID
12559
INTEDE Drug ID
DR0614
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 1B1 (CYP1B1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
Response Summary Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Erythromycin stearate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Erythromycin stearate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Erythromycin stearate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Erythromycin stearate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). [2], [3]
References
Ref 1 LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene. 2020 Jul;39(31):5358-5372. doi: 10.1038/s41388-020-1338-9. Epub 2020 Jun 23.
Ref 2 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72. doi: 10.1016/s0742-8413(98)10036-1.
Ref 3 METTL3 contributes to renal ischemia-reperfusion injury by regulating Foxd1 methylation. Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F839-F847. doi: 10.1152/ajprenal.00222.2020. Epub 2020 Sep 21.